HALO
Halozyme Therapeutics Inc
Price:  
43.82 
USD
Volume:  
898,675.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

HALO EV/EBITDA

87.5%
Upside

As of 2024-05-28, the EV/EBITDA ratio of Halozyme Therapeutics Inc (HALO) is 12.80. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. HALO's latest enterprise value is 6,913.22 mil USD. HALO's TTM EBITDA according to its financial statements is 540.27 mil USD. Dividing these 2 quantities gives us the above HALO EV/EBITDA ratio.

Range Selected
Trailing P/E multiples 19.7x - 25.1x 24.7x
Forward P/E multiples 22.0x - 30.7x 23.5x
Fair Price 64.74 - 96.05 82.15
Upside 47.7% - 119.2% 87.5%
43.82 USD
Stock Price
82.15 USD
Fair Price

HALO EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-05-24 12.80
2024-05-23 12.82
2024-05-22 13.19
2024-05-21 13.20
2024-05-20 13.07
2024-05-17 13.01
2024-05-16 13.17
2024-05-15 13.27
2024-05-14 12.80
2024-05-13 12.75
2024-05-10 12.64
2024-05-09 12.80
2024-05-08 12.37
2024-05-07 12.18
2024-05-06 12.10
2024-05-03 11.87
2024-05-02 11.85
2024-05-01 11.73
2024-04-30 11.45
2024-04-29 11.61
2024-04-26 11.56
2024-04-25 11.53
2024-04-24 11.69
2024-04-23 11.65
2024-04-22 11.59
2024-04-19 11.58
2024-04-18 11.38
2024-04-17 11.43
2024-04-16 11.51
2024-04-15 11.59
2024-04-12 11.57
2024-04-11 11.74
2024-04-10 11.73
2024-04-09 11.93
2024-04-08 11.87
2024-04-05 12.15
2024-04-04 11.83
2024-04-03 11.95
2024-04-02 12.00
2024-04-01 12.21
2024-03-28 12.06
2024-03-27 12.07
2024-03-26 11.91
2024-03-25 11.99
2024-03-22 11.91
2024-03-21 11.95
2024-03-20 11.99
2024-03-19 12.09
2024-03-18 11.98
2024-03-15 12.10